CYP2D6 Genotype–Guided Tamoxifen Dosing in Hormone Receptor–Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype–guided tamoxifen dosing in patients with hormone recept...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tamura, Kenji, Imamura, Chiyo K., Takano, Toshimi, Saji, Shigehira, Yamanaka, Takeharu, Yonemori, Kan, Takahashi, Masato, Tsurutani, Junji, Nishimura, Reiki, Sato, Kazuhiko, Kitani, Akira, Ueno, Naoto T., Mushiroda, Taisei, Kubo, Michiaki, Fujiwara, Yasuhiro, Tanigawara, Yusuke
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7030889/
https://ncbi.nlm.nih.gov/pubmed/31821071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01412
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados